Clinical Trial News

The JAKARTA trial evaluated fedratinib's efficacy and safety in JAK-inhibitor-naïve MF patients, showing significant spleen volume and symptom response improvements over placebo. JAKARTA2 assessed fedratinib in ruxolitinib-treated patients, demonstrating clinical activity with notable spleen volume and symptom response rates, supporting its use in MF treatment.

The results of the MOSAIC study, focusing on the utility, safety, and efficacy of the alfapump in managing recurrent and refractory ascites in liver disease patients, have been published in Liver Transplantation. The study highlights the alfapump's potential to improve quality of life and reduce the need for large-volume paracentesis in cirrhosis patients not suitable for TIPS.

A study reveals that Glycogen Synthase Kinase-3 (GSK-3) inhibition can overcome epithelial-mesenchymal transition (EMT)-mediated resistance to osimertinib in EGFR-mutant non-small cell lung cancer (NSCLC), offering a potential therapeutic strategy for patients with acquired resistance to EGFR-TKIs.

Karyopharm Therapeutics Inc. initiated a Phase 1/2 clinical trial for selinexor combined with standard therapy in glioblastoma (GBM) patients. Selinexor, an XPO1 inhibitor, shows promise in GBM treatment, with previous studies indicating its ability to cross the blood-brain barrier and exhibit anti-GBM activity. The trial aims to evaluate selinexor's efficacy in newly diagnosed and recurrent GBM patients, with primary endpoints focusing on progression-free and overall survival.

A University of Minnesota trial has concluded that hydroxychloroquine is no more effective than a placebo in preventing COVID-19 after exposure, with 40% of participants experiencing non-serious side effects.

10 male LHON patients completed SES sessions, showing significant BCVA improvement post-treatment. Younger age at onset correlated with better SES effectiveness, regardless of treatment timing. Visual field sensitivity changes varied, with some cases improving and others deteriorating.

Malaria causes over 200 million cases and 400,000 deaths annually, with African children and pregnant women at highest risk. Vaccines targeting Plasmodium's life cycle stages are crucial. LMIV, established in 2009, focuses on malaria vaccine development, combining basic research and product development to advance vaccine candidates, including the leading TBV candidate Pfs230D1, currently in phase 2 trials in Mali.

A study by The Chinese University of Hong Kong reveals that performing endoscopy within 6 hours for acute upper gastrointestinal bleeding does not lower mortality or reduce the risk of further bleeding compared to endoscopy performed between 6 and 24 hours after consultation.

An adult with congenital blindness received the first in vivo CRISPR-based therapy, EDIT-101, targeting a CEP290 gene mutation causing Leber congenital amaurosis. This therapy uses AAV5 with guide RNAs and Cas9 enzyme to correct the mutation, differing from Luxturna, which introduces a correct gene copy for RPE65 mutations.

Meta-analysis shows CDK 4/6 inhibitors plus ET improve PFS and OS in HR+/HER2- ABC, despite higher grade 3/4 AEs risk, outperforming ET alone across treatment lines and menopausal statuses.